Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0532 in Advanced Solid Tumors
NCT07749703Phase 1Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SIM0532 in solid tumor, pancreatic adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 21 days, Incidence and severity of adverse events and serious adverse events and 1 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
SIM0532
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07749703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749703.